Citi raised the firm’s price target on Gilead (GILD) to $156 from $140 and keeps a Buy rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are “beatable” and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- Gilead price target raised to $155 from $145 at UBS
- Why Gilead Sciences Is Suddenly Back in the Spotlight
- Gilead announces NEJM Phase 3 study data for Trodelvy+Keytruda
- AbbVie (ABBV) Commits $100B in U.S. Investment, Inks Deal with Trump to Avoid Tariffs